IL155360A0 - Processes for the isolation or purification of plavastatin and compositions containing plavastatin - Google Patents

Processes for the isolation or purification of plavastatin and compositions containing plavastatin

Info

Publication number
IL155360A0
IL155360A0 IL15536001A IL15536001A IL155360A0 IL 155360 A0 IL155360 A0 IL 155360A0 IL 15536001 A IL15536001 A IL 15536001A IL 15536001 A IL15536001 A IL 15536001A IL 155360 A0 IL155360 A0 IL 155360A0
Authority
IL
Israel
Prior art keywords
plavastatin
isolation
purification
processes
compositions containing
Prior art date
Application number
IL15536001A
Other languages
English (en)
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=18794392&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL155360(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of IL155360A0 publication Critical patent/IL155360A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/48—Separation; Purification; Stabilisation; Use of additives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/02—Oxygen as only ring hetero atoms
    • C12P17/06—Oxygen as only ring hetero atoms containing a six-membered hetero ring, e.g. fluorescein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/48—Separation; Purification; Stabilisation; Use of additives
    • C07C67/58—Separation; Purification; Stabilisation; Use of additives by liquid-liquid treatment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/48—Separation; Purification; Stabilisation; Use of additives
    • C07C67/60—Separation; Purification; Stabilisation; Use of additives by treatment giving rise to chemical modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
    • C07C69/22—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety
    • C07C69/33—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety esterified with hydroxy compounds having more than three hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/62—Carboxylic acid esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/26—All rings being cycloaliphatic the ring system containing ten carbon atoms
    • C07C2602/28—Hydrogenated naphthalenes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL15536001A 2000-10-16 2001-10-15 Processes for the isolation or purification of plavastatin and compositions containing plavastatin IL155360A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000315256A JP3236282B1 (ja) 2000-10-16 2000-10-16 プラバスタチンを精製する方法
PCT/JP2001/009045 WO2002032848A1 (fr) 2000-10-16 2001-10-15 Procede de purification de pravastatine

Publications (1)

Publication Number Publication Date
IL155360A0 true IL155360A0 (en) 2003-11-23

Family

ID=18794392

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15536001A IL155360A0 (en) 2000-10-16 2001-10-15 Processes for the isolation or purification of plavastatin and compositions containing plavastatin

Country Status (19)

Country Link
US (1) US20030216596A1 (cs)
EP (4) EP1514862A1 (cs)
JP (1) JP3236282B1 (cs)
KR (1) KR20030042018A (cs)
CN (4) CN1868996A (cs)
AU (1) AU2001294258A1 (cs)
BR (1) BR0114681A (cs)
CA (1) CA2425883A1 (cs)
CZ (1) CZ20031052A3 (cs)
HU (1) HUP0303106A3 (cs)
IL (1) IL155360A0 (cs)
MX (1) MXPA03003347A (cs)
NO (1) NO20031739L (cs)
NZ (3) NZ536892A (cs)
PL (1) PL360934A1 (cs)
RU (2) RU2260582C2 (cs)
SK (1) SK4532003A3 (cs)
WO (1) WO2002032848A1 (cs)
ZA (1) ZA200302966B (cs)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3422791B2 (ja) 2002-08-06 2003-06-30 三共株式会社 プラバスタチンの単離・精製方法
TW589178B (en) * 2003-02-21 2004-06-01 China Chemical & Pharmaceutica A novel industrial process to obtain pravastatin sodium of high purity
EP1452519A1 (en) * 2003-02-25 2004-09-01 Balkanpharma-Razgrad AD Method for the isolation and purification of pravastatin sodium
BRPI0513082A (pt) * 2004-08-06 2008-04-22 Transform Pharmaceuticals Inc formulações de fenofibrato e métodos de tratamento relacionados
US7642287B2 (en) * 2004-08-06 2010-01-05 Transform Pharmaceuticals, Inc. Statin pharmaceutical compositions and related methods of treatment
US20090042979A1 (en) * 2004-08-06 2009-02-12 Transform Pharmaceuticals Inc. Novel Statin Pharmaceutical Compositions and Related Methods of Treatment
CN100361954C (zh) * 2005-05-16 2008-01-16 天津市冠东科技有限公司 制备普伐他汀结晶体的干燥方法
JP4813841B2 (ja) * 2005-07-25 2011-11-09 キユーピー株式会社 プラバスタチンナトリウムの製造方法
US8734795B2 (en) * 2008-10-31 2014-05-27 Biogen Idec Ma Inc. Light targeting molecules and uses thereof
CN109796333B (zh) * 2019-01-25 2021-04-09 北大方正集团有限公司 一种从发酵液中提取纯化普伐他汀钠的方法
CN112778120B (zh) * 2019-11-08 2024-05-17 上海现代制药股份有限公司 一种降血脂类药物氧化杂质的制备方法
CN119915919A (zh) * 2023-10-31 2025-05-02 上海现代制药股份有限公司 普伐他汀有关物质的检测方法
CN119915920A (zh) * 2023-10-31 2025-05-02 上海现代制药股份有限公司 普伐他汀有关物质的检测方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK149080C (da) * 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
JPS5889191A (ja) * 1981-11-20 1983-05-27 Sankyo Co Ltd ３−ヒドロキシ−ｍｌ−２３６ｂ誘導体の製造法
US5202029A (en) 1991-03-13 1993-04-13 Caron Kabushiki Kaisha Process for purification of hmg-coa reductase inhibitors
NZ250609A (en) * 1992-12-28 1995-07-26 Sankyo Co Hexahydronaphthalene esters and ring closed lactones; preparation and medicaments
IL108432A (en) * 1993-01-29 1997-09-30 Sankyo Co DERIVATIVES OF 3, 5-DIHYDROXY-7- £1, 2, 6, 7, 8, 8a-HEXAHYDRO-2- METHYL-8- (SUBSTITUTED ALKANOYLOXY)-1-NAPHTHYL| HEPTANOIC ACID AND THEIR LACTONES, THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
MX9702403A (es) * 1995-08-03 1997-06-28 Gist Brocades Bv Procedimiento selectivo para la desacilacion de compuestos acilados.
SI9800046A (sl) 1998-02-18 1999-08-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Postopek za pridobivanje inhibitorjev HMG-CoA reduktaze visoke čistosti
SI20305A (sl) * 1999-08-06 2001-02-28 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Kristali natrijeve soli pravastatina
SI20072A (sl) 1998-09-18 2000-04-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Postopek za pridobivanje inhibitorjev HMG-CoA reduktaze
JP2000279174A (ja) 1999-03-30 2000-10-10 Bml Inc ヒトｌｄｌレセプターに対するモノクローナル抗体及びこれを用いる家族性高脂血症の判定方法
HUP9902352A1 (hu) * 1999-07-12 2000-09-28 Gyógyszerkutató Intézet Kft. Eljárás pravasztatin mikrobiológiai előállítására
CZ20031166A3 (cs) * 2000-10-05 2004-04-14 Biogal Gyogyszergyar Rt Sodná sůl pravastatinu, která v podstatě neobsahuje pravastatin lakton a epi-pravastatin a kompozice na její bázi

Also Published As

Publication number Publication date
EP1327626A4 (en) 2004-08-18
NZ536891A (en) 2005-05-27
SK4532003A3 (en) 2003-10-07
MXPA03003347A (es) 2003-06-19
CN1868996A (zh) 2006-11-29
WO2002032848A1 (fr) 2002-04-25
CN1679535A (zh) 2005-10-12
NO20031739L (no) 2003-06-13
EP1514863A1 (en) 2005-03-16
AU2001294258A1 (en) 2002-04-29
NZ525256A (en) 2005-01-28
NO20031739D0 (no) 2003-04-15
JP2002121174A (ja) 2002-04-23
PL360934A1 (en) 2004-09-20
US20030216596A1 (en) 2003-11-20
EP1522589A1 (en) 2005-04-13
CZ20031052A3 (cs) 2003-09-17
HUP0303106A3 (en) 2004-10-28
EP1327626A1 (en) 2003-07-16
RU2005113661A (ru) 2006-11-10
ZA200302966B (en) 2004-07-15
KR20030042018A (ko) 2003-05-27
CN1481353A (zh) 2004-03-10
BR0114681A (pt) 2003-12-09
NZ536892A (en) 2005-05-27
EP1514862A1 (en) 2005-03-16
CA2425883A1 (en) 2003-04-15
CN1690037A (zh) 2005-11-02
JP3236282B1 (ja) 2001-12-10
RU2260582C2 (ru) 2005-09-20
HUP0303106A2 (hu) 2003-12-29

Similar Documents

Publication Publication Date Title
AU3276802A (en) Background of the invention
HUP0302922A3 (en) Imidazolo-5-yl-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation and pharmaceutical compositions containing them
AUPR105400A0 (en) Processes and compositions for water treatment
PL359064A1 (en) Novel compounds of the n-acylamino-amide family, compositions comprising same, and uses
AU2001239052A1 (en) Compositions for prevention and treatment of dementia
PL345315A1 (en) Treatment of airborne microorganisms
HUP0302721A3 (en) Processes for the purification of higher diamondoids and compositions comprising such diamondoids
IL155360A0 (en) Processes for the isolation or purification of plavastatin and compositions containing plavastatin
HUP0302579A3 (en) Process for the isolation and purification of epothilones
PL359560A1 (en) Process for the isolation of lovastatin
GB0011186D0 (en) Modification of bacteria
AU8824201A (en) Process for the preparation of dinapsoline
GB0029903D0 (en) Use of anti-muscarinic agents
IL156359A0 (en) Process for the preparation of 4-haloalkylnicotinonitriles
AU2002303552A8 (en) Methods and compositions for prevention of angioproliferation
AU7402201A (en) Use of substituted 1-amino-5-phenylpentane-3-ol and/or 1-amino-6-phenylhexane-3-ol compounds as medicaments
AU2002359792A8 (en) Methods and compositions for the inhibition of viral release
IL150897A0 (en) Process for the preparation of acetyl-amidiniophenylalanyl cyclohexylglycyl-pyridinioalaninamides
AU2001286489A1 (en) Process for the purification of iosoctane and/or diisobutylene
IL190807A0 (en) Process for the preparation of 2-aminoethylpyridines
GB0019350D0 (en) Protection of vessels
GB0012249D0 (en) Process for the preparation of 11-oxaprostaglandins
SI1289514T1 (en) Use of substituted 1-amino-5-phenylpentane-3-ol and/or 1-amino-6-phenylhexane-3-ol compounds as medicaments
HU0104528D0 (en) Process for the preparation and use of biocide compositions
AU2001273847A1 (en) Polydesoxyribonucleotides for inhibiting the expression of the icam-1-gene